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Artemisia annua extract prevents 
ovariectomy-induced bone loss 
by blocking receptor activator of 
nuclear factor kappa-B ligand-
induced differentiation of 
osteoclasts
Sun Kyoung Lee1, Hyungkeun Kim1,2, Junhee Park1,3, Hyun-Jeong Kim1, Ki Rim Kim4, Seung 
Hwa Son5, Kwang-Kyun Park1,2,3 & Won-Yoon Chung  1,2,3
The activities of osteoclasts and osteoblasts are balanced to maintain normal bone density. Many 
pathological conditions cause osteoclastic bone resorption in excess of osteoblastic bone formation, 
resulting in osteoporosis. We found that oral administration of Artemisia annua ethanol extract 
(AaE) or major components, artemisinin and arteannuin B, to ovariectomized (OVX) mice prevented 
bone loss, as verified by examining three-dimensional images and bone morphometric parameters 
derived from microcomputed tomography analysis, as well as serum levels of bone turnover markers 
and proinflammatory cytokines. The administered doses were not toxic to the liver or kidney and 
showed promising effects that were comparable to those of 17β-estradiol treatment. At non-cytotoxic 
concentrations, AaE and active components, artemisinin, artemisinic acid, and arteannuin B, potently 
inhibited receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastogenesis and 
the formation of osteoclast-mediated resorption pits. Furthermore, AaE, artemisinin, and arteannuin 
B remarkably reduced the expression of the c-Fos and NFATc1 transcription factors, which play critical 
roles in RANKL-induced osteoclast differentiation. Taken together, the in vivo anti-osteoporotic 
activity of AaE may be derived from the anti-osteoclastic and anti-bone resorptive activities of its active 
components. AaE has beneficial applications for the prevention and inhibition of osteoporosis and 
osteoclast-mediated bone diseases.
Bone homeostasis is maintained by osteoclasts and osteoblasts1. Osteoclasts, which are derived from monocytes 
and macrophages, degrade the bone matrix2. Mesenchymal stem cell-derived osteoblasts rebuild the resorbed 
bone and regulate osteoclast differentiation via receptor activator of nuclear factor kappa-B ligand (RANKL) 
and osteoprotegerin (OPG) expression3. When exposed to pathological conditions, such as estrogen deficiency, 
inflammation, and metastatic cancer, osteoclastic bone resorption surpasses osteoblastic bone formation4,5. This 
excessive osteoclast activity causes many bone diseases, including osteoporosis, rheumatoid arthritis, periodontal 
disease, and cancer-induced osteolysis6–8. Postmenopausal osteoporosis is an important public health problem 
worldwide9.
Most therapeutic agents for the treatment of osteoporosis and other bone diseases are designed to inhibit 
bone resorption by osteoclasts or stimulate bone formation by osteoblasts10. Unfortunately, these therapeutic 
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agents have considerable side effects. The long-term use of bisphosphonates can lead to osteonecrosis of the jaw, 
nephrotoxicity, and atypical subtrochanteric femoral fractures, and estrogen replacement therapy can elevate the 
risk of cardiovascular disease and breast cancer11–13. Transient increases in serum and urine calcium levels have 
been reported in patients treated with teriparatide. Furthermore, denosumab, a full human monoclonal antibody 
against RANKL, is contraindicated in patients with hypocalcemia because it can reduce serum calcium level14–16. 
Therefore, it is necessary to find new agents for the management of osteoporosis.
Medicinal plants with multiple active components have been used to treat a variety of diseases in Asian countries17–20. 
Artemisia annua L. (Asteraceae) is a traditional herbal medicine with a long history of safe use for the treatment 
of malaria. It is the source of artemisinin, an anti-malarial agent with a sesquiterpene trioxane lactone21. Because 
of the presence of flavonoids, essential oils, and sesquiterpene lactones, A. annua has anti-oxidant, anti-cancer, 
anti-microbial, anti-adipogenic, and anti-inflammatory activities22–26. Many studies have used artemisinin, iso-
lated from A. annua, and its natural and semi-synthetic derivatives to develop more effective anti-malarial agents 
and to find new treatments for other diseases, including cancer27–30.
In the present study, we investigated the protective effects of A. annua extract and its active components 
on bone loss in ovariectomized (OVX) mice. We further examined the inhibitory effects of A. annua extract, 
artemisinin, artemisinic acid, and arteannuin B on osteoclast formation and the expression of related transcrip-
tion factors, as well as the function of mature osteoclasts, in RANKL-treated mouse bone marrow-derived mac-
rophages (BMMs).
Results
A. annua extract and its active components inhibited bone loss in OVX mice. We first assessed 
the anti-osteoporotic effects of A. annua ethanol extract (AaE) in OVX mice, an animal model of estrogen defi-
ciency-induced osteoporosis. Oral administration of AaE did not suppress OVX-induced weight gain, but the 
positive control, 17β-estradiol (E2), did (Supplementary Fig. S1a). Three-dimensional (3D) images of femora 
that were reconstructed using microcomputed tomography (μCT) analysis clearly showed that OVX-induced 
trabecular bone loss was inhibited by AaE treatment in a dose-dependent manner (Fig. 1a). Bone morphometric 
parameters, including bone volume over total volume (BV/TV) and trabecular number (Tb.N), were decreased, 
whereas trabecular separation (Tb.Sp) was increased in the distal femora of the OVX-mice compared with the 
sham-operated mice. OVX-related changes in bone morphometric parameters were markedly suppressed by AaE 
treatment. Statistically significant alterations in trabecular thickness (Tb.Th) and the structure model index (SMI) 
were not detected in the femora of these OVX mice regardless of AaE treatment (Fig. 1b). H&E and TRAP stain-
ing indicated that AaE treatment inhibited OVX-induced bone loss and the formation of TRAP-positive osteo-
clasts on the bone surfaces (Fig. 1c,d). The serum levels of bone turnover markers, including alkaline phosphatase 
(ALP), osteocalcin, calcium, tartrate-resistant acid phosphatase 5b (TRAP 5b), and C-terminal cross-linking 
telopeptide of type Ι collagen (CTX), were increased in the OVX-mice. Oral administration of AaE significantly 
reduced the levels of these osteoporosis-related serum markers (Fig. 1e). Moreover, AaE administration to OVX 
mice inhibited the increase in the serum levels of tumor necrosis factor (TNF)-α and interleukin (IL)-1β, which 
are proinflammatory cytokines that play critical roles in estrogen deficiency-induced bone loss31 (Fig. 1f).
Next, we verified that orally administered artemisinin or arteannuin B, major components of AaE, signifi-
cantly inhibited OVX-induced weight gain (Supplementary Fig. S1b) and OVX-induced trabecular bone loss, 
as shown by 3D images of femora (Fig. 2a), bone morphometric parameters (Fig. 2b), H&E and TRAP staining 
(Fig. 2c,d), and the serum levels of bone turnover markers (Fig. 2e) and proinflammatory cytokines (Fig. 2f).
As expected, the treatment with AaE, artemisinin, or arteannuin B did not result in elevated serum levels 
of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which are indicative of liver damage 
(Supplementary Fig. S1c), or of blood urea nitrogen (BUN) and creatinine, which are indicative of kidney damage 
(Supplementary Fig. S1d).
A. annua extract suppressed RANKL-induced osteoclast formation and function. To exam-
ine the effects of AaE on osteoclast differentiation and activity, we identified non-cytotoxic concentrations of 
AaE using BMMs, which are osteoclast precursors, via an MTT assay. The viability of the AaE-treated BMMs 
was 79.7% at 5 μg/mL and 65.2% at 10 μg/mL (IC50 = 27.1 μg/mL) (Fig. 3a). When the BMMs were treated with 
RANKL in the presence of AaE for 5 days and then stained for TRAP, osteoclast formation was inhibited by 
42.4% at 5 μg/mL and by 85.2% at 10 μg/mL (Fig. 3b). The anti-bone resorptive activity of AaE was assessed 
by measuring the area of the pits produced by RANKL-induced mature osteoclasts in plates coated with bone 
mimetic material. AaE markedly reduced the area of the resorption pits by 64.8% at 5 μg/mL and by 88.3% at 
10 μg/mL (Fig. 3c). Gelatin zymography indicated that AaE did not inhibit the activities of matrix metalloprotein-
ase (MMP)-2 and MMP-9 in the culture media of the RANKL-induced mature osteoclasts (Fig. 3d). Cathepsin K 
activity was decreased by 11.2% and 54.3% in the culture medium and lysate, respectively, of the RANKL-induced 
mature osteoclasts treated with 10 μg/mL AaE (Fig. 3e).
Artemisinin, artemisinic acid, and arteannuin B interrupted RANKL-induced osteoclast for-
mation. We assessed the anti-osteoclastic activities of artemisinin, artemisinic acid, and arteannuin B, 
which are known to be the active components of A. annua32. The results of the MTT assay indicated that arte-
misinin (Fig. 4a) and artemisinic acid (Fig. 4b) were not cytotoxic to the BMMs at concentrations of less than 
80 μM. Arteannuin B significantly decreased the viability of the BMMs at concentrations of more than 5 μM 
(IC50 = 7.3 μM) (Fig. 4c). Artemisinin and arteannuin B significantly inhibited RANKL-induced osteoclast for-
mation by 29.5% and 41.9% at 1 μM and by 79.6% and 98.2% at 5 μM, respectively. Artemisinic acid suppressed 
RANKL-induced osteoclastogenesis by 87.9% at 80 μM in BMMs (Fig. 4d).
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Figure 1. AaE inhibits OVX-induced bone loss in mice. Eight-week-old female OVX mice (N = 10) were 
administered vehicle (PBS containing 1% DMSO and 1% Tween-20), 1 or 10 mg/kg BW of AaE, or 0.1 mg/
kg BW of E2 by oral gavage 5 times per week for 12 weeks. Sham-operated mice (N = 10) received the vehicle 
alone. (a) The trabecular bones of the distal femora of mice were scanned using μCT at 12 weeks, and 3D 
images were obtained as described in the Methods section. One representative image is shown per group. 
(b) Bone morphometric parameters of the mouse femora, including BV/TV, Tb.N, Tb.Th, Tb.Sp, and SMI, 
were measured using μCT. (c) H&E and TRAP staining were performed in the sectioned femoral tissues. EP: 
epiphyseal plate. Scale bar: 0.396 mm for H&E staining and 10 μm for TRAP staining. (d) Osteoclast surface per 
bone perimeter (Oc.S/BPm) values were calculated from TRAP-stained femoral sections. (e) Serum levels of 
bone turnover markers and (f) the pro-inflammatory cytokines TNF-α and IL-1β were quantified using their 
respective assay kits as described in the Methods section. The data are expressed as the mean ± SE. #P < 0.01 
versus sham-operated mice (S), *P < 0.05, **P < 0.01 versus OVX mice.
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Figure 2. Artemisinin and arteannuin B reduce OVX-induced bone loss in mice. Eight-week-old female OVX 
mice (N = 10) were administered vehicle (PBS containing 1% DMSO and 1% Tween-20), 10 or 20 mg/kg BW 
of artemisinin (ART), 20 mg/kg BW of arteannuin B (AB) or 0.1 mg/kg BW of E2 by oral gavage 5 times per 
week for 12 weeks. Sham-operated mice (N = 10) received the vehicle alone. (a) 3D images of the trabecular 
bones in the distal femora of mice were obtained using μCT at 12 weeks as described in the Methods section. 
(b) Bone morphometric parameters of the mouse femora, including BV/TV, Tb.N, Tb.Th, Tb.Sp, and SMI, were 
measured using μCT. (c) H&E and TRAP staining were performed in the sectioned femoral tissues. Arrowhead: 
TRAP-positive osteoclast. Scale bar: 0.396 mm for H&E staining and 10 μm for TRAP staining. (d) Osteoclast 
surface per bone perimeter (Oc.S/BPm) values were calculated from TRAP-stained femoral sections. (e) Serum 
levels of bone turnover markers and (f) the pro-inflammatory cytokines TNF-α and IL-1β were quantified 
using their respective assay kits as described in the Methods section. The data are expressed as the mean ± SE. 
#P < 0.01 versus sham-operated mice (S), *P < 0.05, **P < 0.01 versus OVX mice.
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Artemisinin, artemisinic acid, and arteannuin B inhibited mature osteoclast-mediated bone 
resorption. We evaluated whether artemisinin, artemisinic acid, and arteannuin B could reduce bone 
resorption by mature osteoclasts. BMMs were first stimulated with RANKL to induce differentiation into mature 
Figure 3. AaE suppresses RANKL-induced osteoclastogenesis and the function of mature osteoclasts. (a) 
BMMs were cultured in α-MEM containing M-CSF (30 ng/mL) and AaE at the indicated concentrations 
for 5 days. Cell viability was measured with an MTT assay. The data are expressed as the mean ± SE of 
triplicate experiments. *P < 0.05, **P < 0.01 versus BMMs without AaE. (b) BMMs were incubated in α-MEM 
with M-CSF (30 ng/mL), RANKL (100 ng/mL), and the indicated concentrations of AaE for 5 days. The 
differentiated osteoclasts were detected by TRAP staining, and TRAP-positive multinucleated cells with more 
than 3 nuclei were counted using light microscopy (magnification, ×100). (c) The BMMs were cultured in 
α-MEM containing M-CSF (30 ng/mL) and RANKL (100 ng/mL) onto Osteo Assay Surface Plates for 5 days. 
The cells were then treated with the indicated concentrations of AaE for an additional 2 days. The resorption 
pits (*) were observed using light microscopy (magnification, ×100), and the resorbed area was calculated 
using ImageJ software. (d) MMP-2 and MMP-9 activities in the culture media of osteoclasts were detected 
by gelatin zymography as described in the Methods section. (e) Cathepsin K activity in the culture media and 
lysates of the osteoclasts was measured using a commercially available cathepsin K assay kit according to the 
manufacturer’s instructions. The images are representative, and the data are expressed as the mean ± SE of 
triplicate experiments. #P < 0.01 versus BMMs without RANKL (C), *P < 0.05, **P < 0.01 versus BMMs with 
RANKL alone.
www.nature.com/scientificreports/
6Scientific REPORTS | 7: 17332  | DOI:10.1038/s41598-017-17427-6
osteoclasts on an Osteo Assay Surface Plate to assess pit formation and then treated with artemisinin, artemisinic 
acid, or arteannuin B. Artemisinin at 5 μM and artemisinic acid at 80 μM inhibited the formation of resorption 
pits by RANKL-induced osteoclasts by 34.2% and 30.4%, respectively. Treatment with 5 μM arteannuin B weakly 
showed minimal effects on the formation of resorption pits (Fig. 5a). The activities of MMP-2 and MMP-9 in the 
culture media of RANKL-induced mature osteoclasts were inhibited by artemisinic acid and arteannuin B, but 
not by artemisinin (Fig. 5b). Cathepsin K levels were reduced by 18.3% and 25.2% in the culture media of oste-
oclasts treated with 5 μM artemisinin and 80 μM artemisinic acid, respectively. However, arteannuin B did not 
show any significant inhibitory effects (Fig. 5c).
A. annua extract and its bioactive components suppressed the expression of key transcription 
factors in RANKL-induced osteoclastogenesis. To determine the molecular mechanisms by which AaE 
and its active components inhibit the RANKL-induced differentiation of osteoclast precursor cells, we examined 
the expression levels of c-Fos and NFATc1, which are osteoclastogenic transcription factors33–35, in the cell lysates 
of RANKL-treated BMMs using western blot analysis. RANKL stimulation clearly increased the expression of 
both c-Fos and NFATc1. However, AaE treatment significantly inhibited the RANKL-induced protein expression 
of c-Fos and NFATc1 in a dose-dependent manner (Fig. 6a). Artemisinin and arteannuin B suppressed c-Fos 
and NFATc1 protein expression in the RANKL-treated BMMs but artemisinic acid did not show any significant 
inhibitory effects (Fig. 6b). qRT-PCR data indicated that AaE and its active components also inhibited c-Fos and 
NFATc1 mRNA expression (Fig. 6c).
Figure 4. The active components of A. annua attenuate RANKL-induced osteoclast formation. The BMMs were 
cultured with M-CSF (30 ng/mL) and the indicated concentrations of (a) artemisinin (ART), (b) artemisinic 
acid (AA), or (c) arteannuin B (AB) for 5 days. Cell viability was determined using an MTT assay. The data are 
expressed as the mean ± SE. *P < 0.05, **P < 0.01 versus BMMs without active components. (d) BMMs were 
incubated in media with M-CSF (30 ng/mL), RANKL (100 ng/mL), and the indicated concentration of ART, 
AA, or AB for 5 days. Mature osteoclasts were detected by TRAP staining and TRAP-positive multinucleated 
cells were counted using light microscopy (magnification, ×100). The images are representative, and the data 
are expressed as the mean ± SE of triplicate experiments. #P < 0.01 versus BMMs without RANKL (C), *P < 0.05, 
**P < 0.01 versus BMMs with RANKL alone.
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Discussion
In the present study, we attempted to verify the potential of AaE and its active components for the prevention and 
inhibition of osteoporosis. Our in vivo study demonstrated that oral administration of AaE and its active com-
ponents, artemisinin and arteannuin B, protected against estrogen deficiency-induced bone loss by significantly 
blocking ovariectomy-induced alterations in bone architecture parameters, serum bone turnover markers and 
the pro-inflammatory cytokines TNF-α and IL-1β. According to accumulating data, estrogen deficiency-induced 
bone loss is widely considered to be closely linked to pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, 
and IL-1136. These pro-inflammatory cytokines have been reported to either directly or indirectly stimulate the 
bone-resorptive activity of osteoclasts37. Estrogen deficiency leads to a global increase in IL-7 production in the 
thymus and spleen, as well as in bone. The produced IL-7 induces TNF release from activated T cells and also 
stimulates T cell proliferation and activation. TNF, in turn, promotes the production of RANKL, M-CSF, IL-1, 
and IL-6 by stromal and osteoblastic cells, stimulating the differentiation of osteoclast precursors31,38. Notably, 
oral administration of AaE, artemisinin, and arteannuin B at the doses used in this study did not result in damage 
to the liver or kidney and was as effective as oral administration of 17β-estradiol. These results suggest that AaE 
and its major components are safe and have excellent anti-osteoporotic activity.
To support the in vivo anti-osteoporotic activity of AaE, we investigated the inhibitory effect of AaE on oste-
oclast formation and function. Two biosynthetic pathways have been reported in A. annua. One route leads to 
the production of artemisinin, and the other leads to the production of arteannuin B. Artemisinic aldehyde is 
biosynthesized from farnesyl diphosphate and converted to artemisinin and deoxyartemisinin via dihydroar-
temisinic aldehyde and dihydroartemisinic acid. On the other hand, the intermediate, artemisinic aldehyde, is 
oxidized to artemisinic acid, and artemisinic acid is then converted to arteannuin B39. Although AaE contains 
a number of other compounds, artemisinin, arteannuin B, and their biosynthetic precursors are considered the 
major active components40,41. In this study, we further examined anti-osteoclastic and anti-bone resorptive activ-
ities of artemisinin, arteannuin B, and artemisinic acid as the bioactive components of AaE. Treatment with 
AaE or these active components at non-cytotoxic concentrations reduced RANKL-induced osteoclastogene-
sis in the osteoclast precursors, BMMs. Osteoclast differentiation is triggered by the binding of osteoblastic/
stromal RANKL to RANK in osteoclast precursors33,42. This binding activates the transcription factor complex 
AP-1 partly through induction of its critical component, c-Fos35. NFATc1, a key transcriptional regulator of 
Figure 5. The active components inhibit the activity of RANKL-induced osteoclasts. BMMs were seeded onto 
Osteo Assay Surface Plates and incubated in α-MEM containing M-CSF (30 ng/mL) and RANKL (100 ng/
mL) for 5 days. The cells were then exposed to the indicated concentrations of artemisinin (ART), artemisinic 
acid (AA), or arteannuin B (AB) for an additional 2 days. (a) The cells were lysed with 5% sodium hypochlorite 
solution, and the formed resorption pits were examined using light microscopy (magnification, ×100). The 
resorbed area was calculated using ImageJ software. (b) MMP-2 and MMP-9 activities and (c) cathepsin K 
activity were detected using gelatin zymography and a commercially available cathepsin K assay kit. The images 
are representative, and the data are expressed as the mean ± SE of triplicate experiments. #P < 0.01 versus BMMs 
without RANKL (C), *P < 0.05, **P < 0.01 versus BMMs with RANKL alone.
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osteoclast differentiation, is also activated by RANKL-RANK binding and subsequently enhances the expression 
of osteoclast-specific molecules, including TRAP and cathepsin K, in cooperation with c-Fos34,43. AaE, artemis-
inin, and arteannuin B markedly suppressed the protein and mRNA expressions of c-Fos and NFATc1, thereby 
inhibiting RANKL-induced osteoclastogenesis. At relatively high concentrations, artemisinic acid reduced the 
expression of these transcription factors. These results suggest that the anti-osteoclastic activity of AaE is due 
to the ability of artemisinin and arteannuin B to downregulate RANKL-induced c-Fos and NFATc1 expression.
Mature osteoclasts adhere to bone surfaces and secrete protons, which are generated by carbonic anhydrase; 
proteases, such as cathepsin K, that are released by lysosomes; and MMPs to stimulate the release of inorganic 
ions and degrade collagen in the bone44,45. In this study, AaE significantly inhibited the formation of resorption 
pits by RANKL-induced mature osteoclasts on bone-mimetic plates. AaE did not reduce the secretion of MMP-2 
and MMP-9, but it decreased the production and secretion of cathepsin K. Artemisinin, arteannuin B, and arte-
misinic acid, also attenuated RANKL-induced pit formation. At the same concentrations, artemisinin inhib-
ited the secretion of cathepsin K but not of MMPs. Arteannuin B did inhibit MMP-2/9 levels. Artemisinic acid 
decreased the activities of MMP-2/9 and cathepsin K at relatively higher concentrations. However, the anti-bone 
resorptive activities of these active components were not as strong as their anti-osteoclastic activities. These data 
reveal that the anti-bone resorptive activity of AaE may be attributed to the anti-osteoclastic activities of the 
three components, despite their inhibition of pit formation and bone matrix-degrading proteinase activities. In 
contrast, AaE and active components did not induce the activation of osteoblasts at non-cytotoxic concentrations 
(Supplementary Fig. S2).
Additionally, we examined the effect of AaE and the three components on the levels of osteoblast-derived 
RANKL and OPG. Whereas RANKL promotes osteoclast differentiation via RANK, OPG blocks osteoclast 
Figure 6. AaE and its active components suppress c-Fos and NFATc1 expression in RANKL-treated BMMs. 
BMMs were incubated with M-CSF (30 ng/mL), RANKL (50 ng/mL), and the indicated concentrations of 
(a) AaE and (b) artemisinin (ART), artemisinic acid (AA), or arteannuin B (AB) for 2 days. The expression 
levels of c-Fos and NFATc1 were examined by western blot analysis. The band intensity of each protein was 
densitometrically measured with TINA software and normalized to that of GAPDH as an internal control. The 
images are representative. (c) The mRNA expression levels of c-Fos and NFATc1 were detected using qRT-PCR 
and normalized to that of GAPDH. The data are expressed as the mean ± SE of triplicate experiments. #P < 0.01 
versus BMMs without RANKL (C), *P < 0.05, **P < 0.01 versus BMMs with RANKL alone.
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differentiation by sequestering RANKL from RANK2. Because estrogen deficiency-induced pro-inflammatory 
cytokines are directly involved in RANKL production46, we examined whether treatment with AaE could affect 
RANKL and OPG production in two human osteoblastic cell lines stimulated with either TNF-α or IL-1β 
(Supplementary Fig. S3). Treatment with TNF-α and IL-1β increased the secretion of both RANKL and OPG, 
and AaE treatment decreased the secretion of these proteins by TNF-α or IL-1β. However, the RANKL/OPG 
ratio was not noticeably changed by treatment with the proinflammatory cytokines and AaE. These data indicate 
that AaE may inhibit bone loss by inhibiting RANKL-induced osteoclast differentiation, rather than by regulating 
RANKL and/or OPG production in proinflammatory cytokine-stimulated osteoblastic cells.
In summary, AaE, including artemisinin, artemisinic acid, and arteannuin B, inhibited bone loss in 
estrogen-deficient OVX mice. AaE, artemisinin, artemisinic acid, and arteannuin B blocked RANKL-induced 
osteoclast differentiation via c-Fos and NFATc1 activation in precursor cells, as well as the resulting bone resorp-
tion. Taken together, our results indicate that the in vivo anti-osteoporotic effects of AaE may originate from the 
anti-osteoclastic activities of artemisinin, artemisinic acid, and arteannuin B. Therefore, AaE and its active com-
ponents may be beneficial agents with high efficacy and safety for the prevention and treatment of osteoporosis 
and osteoclast-related bone diseases.
Methods
Reagents. A. annua extract (AaE) (MPRBE00725) was provided by the Medicinal Plant Resources Bank 
(http://knrrb.knrrc.or.kr, Seongnam, Korea), which is supported from the Ministry of Science, ICT, and Future 
Planning/National Research Foundation of Korea. Artemisinin was obtained from LKT Laboratories (St. Paul, 
MN), and artemisinic acid and arteannuin B were obtained from ChemFaces (Wuhan, China). Minimum essen-
tial medium-alpha (α-MEM), fetal bovine serum (FBS), phosphate-buffered saline (PBS), and antibiotics were 
purchased from Gibco BRL (Grand Island, NY). Recombinant mouse M-CSF and RANKL were obtained from 
R&D Systems (Minneapolis, MN). Dimethyl sulfoxide (DMSO), 17β-estradiol (E2), Tween-20, 3-(4,5-dime-
thyl-thiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT), and Histopaque-1083 were purchased from Sigma-
Aldrich (St. Louis, MO). Polyclonal anti-c-Fos and anti-NFATc1 and monoclonal anti-GAPDH antibodies were 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). All the reagents used in this study were analytical 
grade.
Animals. Four-week-old male ICR or 8-week-old female sham and ovariectomized ICR mice were purchased 
from NARA Biotech (Seoul, Korea) and Central Lab Animal (Seoul, Korea). The mice were provided free access 
to a standard chow diet (Orient, Seongnam, Korea) and tap water ad libitum. They were housed under specific 
pathogen-free conditions with a 12-h light/dark cycle and a relative humidity of 50 ± 5% at 22 ± 2 °C. All animal 
studies were conducted in accordance with the experimental protocols approved by Institutional Animal Care 
and Use Committee of the Yonsei University College of Dentistry (IACUC Approval No. 2015-0261 and 2016-
0330). All methods were carried out in accordance with relevant guidelines and regulations.
Induction of osteoporosis in OVX mice. Eight-week-old female OVX mice were divided into 4 groups 
of 10 mice and were administered vehicle (PBS containing 1% DMSO and 1% Tween-20), 1 or 10 mg/kg body 
weight (BW) of AaE, or 0.1 mg/kg BW of E2 by oral gavage 5 times per week for 12 weeks. In addition, OVX mice 
were divided into 6 groups of 10 mice and were administered vehicle, 10 or 20 mg/kg BW of artemisinin, 20 mg/
kg BW of arteannuin B, or 0.1 mg/kg BW of E2 by oral gavage 5 times per week for 12 weeks. Sham-operated mice 
received the vehicle alone. Body weights were measured biweekly using an electronic scale. Blood samples were 
collected by cardiac puncture at the end of the experimental period, and the femora were collected. The femora 
were analyzed using a SkyScan 1076 μCT system (SkyScan, Aartselaar, Belgium) with an X-ray source voltage 
of 100 kV, a current of 100 mA, and a 0.5-mm aluminum filter as described previously47. The scanning angu-
lar rotation was 360°, and the angular increment was 0.5°. Two-dimensional (2D) images were generated using 
NRrecon software (SkyScan). After generating the 2D images, 3D microstructural images were reconstructed 
using Rapidform 2006 software (INUS Technology, Seoul, Korea). For the quantitative analysis of bone alteration, 
resident software (CTAn, SkyScan) was used to calculate the following parameters within the volume of interest: 
BV/TV, Tb.Th, Tb.N, Tb.Sp), and SMI.
Determination of bone turnover marker levels in serum. The collected blood samples were allowed 
to clot for 2 h at room temperature and centrifuged at 2000 × g for 20 min to obtain the serum. The following 
kits were used to determine the levels of the bone turnover markers: the QuantiChrom Calcium Assay Kit and 
ALP Assay Kit (BioAssay Systems, Hayward, CA); the TRAP 5b Enzyme Immunoassay (EIA) Kit and RatLaps 
EIA Kit for CTX (Immunodiagnostic Systems, Fountain Hills, AZ); and the Osteocalcin EIA Kit (Biomedical 
Technologies, Stoughton, MA). TNF-α and IL-1β levels were quantified using their respective commercially 
available ELISA kits (R&D Systems). ALT, AST, BUN, and creatinine levels were quantified using EnzyChrom 
ALT and AST Assay Kits and the QuantiChrom Urea and Creatinine Assay Kits (BioAssay Systems).
Histological examination. The collected femora of mice were fixed in 10% buffered formalin solution for 
24 h, decalcified with 10% EDTA solution (pH 7.5) at 4 °C for two weeks and then embedded in paraffin. Serial 
sections (3-4 μm thick) were prepared and mounted onto slides. Hematoxylin-eosin (H&E) and TRAP staining 
were accomplished in the sections derived from mouse hind limbs as described previously48. Osteoclast surface 
per bone perimeter (Oc.S/BPm) values were measured with IMT i-Solution software (version 7.3, IMT i-Solution, 
BC, Canada) and determined as the percentage of bone surface in contact with osteoclasts.
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Cell culture. Mouse BMMs were isolated from the tibiae of four-week-old male ICR mice using Histopaque 
density gradient centrifugation as described previously49 and cultured in α-MEM containing 10% FBS and 30 ng/
mL M-CSF at 37 °C in a humidified atmosphere of 5% CO2.
Cell viability assay. BMMs (1 × 104 cells/well) were seeded onto 96-well plates in α-MEM containing 10% 
FBS, 30 ng/mL M-CSF, and the indicated concentrations of AaE, artemisinin, artemisinic acid, or arteannuin B 
for 5 days. The cell viability was measured using an MTT assay50.
Osteoclast formation assay. BMMs (5 × 104 cells) were cultured in media containing 10% FBS, 30 ng/
mL M-CSF, 100 ng/mL RANKL, and the indicated concentrations of AaE, artemisinin, artemisinic acid, or arte-
annuin B for 5 days. The cells were fixed for 1 min at room temperature, and enzyme histochemistry for TRAP 
was performed using an acid phosphatase leukocyte kit (Sigma-Aldrich). TRAP-positive multinuclear cells (≥3 
nuclei) were counted as osteoclasts.
Pit formation assay. Osteo Assay Surface Plates (Corning, MA) were used for the pit formation assay as 
described previously50. Briefly, BMMs (2 × 104 cells) were seeded onto the plate and cultured in α-MEM con-
taining 10% FBS, M-CSF (30 ng/mL), and RANKL (100 ng/mL) for 5 days. BMMs were then treated with either 
AaE, artemisinin, artemisinic acid, or arteannuin B at the indicated concentrations for an additional 2 days. The 
cells were lysed with 5% sodium hypochlorite solution. The images of the resorption pits were obtained using 
light microscopy. The resorption pit areas were measured using ImageJ software (Ver. 1.6, NIH, Bethesda, MD).
Zymography and cathepsin K assay. The culture media and cell lysates were collected from the pit for-
mation assay49 and centrifuged at 200 × g for 5 min. The activities of MMP-2 and MMP-9 were determined using 
gelatin zymography. The collected conditioned media were electrophoresed on 10% polyacrylamide gels con-
taining 0.8 mg/mL gelatin. The gels were then washed with 2.5% Triton X-100 for 1 h at room temperature and 
incubated in a reaction buffer containing 50 mM Tris-HCl (pH 7.5), 5 mM CaCl2, 200 mM NaCl, and 0.02% Brij 
35 at 37 °C for 24 h. After staining with 0.1% Coomassie Blue R-250, the gelatinase activity was identified as clear 
bands against a blue background. The cathepsin K activity in the culture media and cell lysates was determined 
using the SensoLyte 520 Cathepsin K Assay Kit (Anaspec, CA) according to the manufacturer’s instructions.
Western blot analysis. BMMs (1 × 106 cells) were treated with M-CSF (30 ng/mL), RANKL (100 ng/mL), 
and either AaE, artemisinin, artemisinic acid, or arteannuin B at the indicated concentrations for 48 h. The cells 
were lysed with RIPA buffer and the protein concentrations of the lysates were measured using a bicinchoninic 
acid (BCA) kit (Pierce, Rockford, IL). Equal amounts of protein (20 μg) were loaded onto a sodium dodecyl 
sulfate–polyacrylamide gel and electrophoresed. The blots were transferred to a polyvinylidene difluoride mem-
brane (Millipore, Billerica, MA). The membrane was blocked with 5% skim milk in TBS-T (10 mM Tris, pH 8.0, 
150 mM NaCl, and 0.1% Tween-20) and then incubated with primary antibodies against NFATc1 or GAPDH 
(1:1000) in 3% skim milk or c-Fos (1:1000) in TBS-T with 5% bovine serum albumin for 24 h at 4 °C. After wash-
ing, the blots were incubated for 1 h with secondary antibodies coupled to horseradish peroxidase (1:2000) and 
visualized using an ECL kit. The intensities of the bands were analyzed using TINA software (Ver. 2.0, Raytest, 
Straubenhardt, Germany).
Quantitative real-time PCR. BMMs (1 × 106 cells) were incubated with M-CSF (30 ng/mL), RANKL 
(50 ng/mL), and AaE or its active components at indicated concentrations in 60-mm dish for 48 h. Total RNA was 
isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA) and complementary DNA was synthesized from the 
RNA (1 μg) by the PrimeScript RT reagent kit (Takara Bio, Otsu, Japan). Quantitative real-time PCR (qRT-PCR) 
was performed using the ABI 7300 Real-Time Systems (Applied Biosystems, Forster City, CA) with SYBR Premix 
Ex TaqTM (Takara Bio) according to the manufacturer’s instructions. The qRT-PCR reaction was performed at 
95 °C for 30 s, followed by 40 cycles of 95 °C for 5 s, 60 °C for 34 s. The quantity of each target was normalized to 
GAPDH. Primer sequences were as follows: c-Fos, forward 5′-GGCACTAGAGACG GACAGAT-3′ and reverse 
5′-ACAGCCTTTCCTACTACCATTC-3′; NFATc1, forward 5′-TGTCTGTGCTCTGCTTCTC-3′ and reverse 
5′-GTCTTCCGA GTTCACATCCC-3′; and GAPDH, forward 5′-GTGGAGTCATACTGGAACATGTAG-3′ 
and reverse 5′-AATGGT GAAGGTCGGTGTG-3′.
Statistical analysis. Statistical analysis was performed using SPSS software ver. 20.0 (SPSS, Inc., Chicago, IL, 
USA). The data are expressed as the mean ± standard error (SE) and were analyzed using one-way ANOVA and 
Tukey test to examine the differences between the two groups. Results with P < 0.05 were considered statistically 
significant.
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